推薦產品
等級
pharmaceutical primary standard
API 家族
cefpodoxime
製造商／商標名
EDQM
應用
pharmaceutical (small molecule)
形式
neat
儲存溫度
−20°C
SMILES 字串
[s]1c(nc(c1)\C(=N\OC)\C(=O)N[C@H]2[C@H]3SCC(=C(N3C2=O)C(=O)OC(OC(=O)OC(C)C)C)COC)N
InChI
1S/C21H27N5O9S2/c1-9(2)33-21(30)35-10(3)34-19(29)15-11(6-31-4)7-36-18-14(17(28)26(15)18)24-16(27)13(25-32-5)12-8-37-20(22)23-12/h8-10,14,18H,6-7H2,1-5H3,(H2,22,23)(H,24,27)/b25-13-/t10?,14-,18-/m1/s1
InChI 密鑰
LTINZAODLRIQIX-FBXRGJNPSA-N
尋找類似的產品？ 前往 產品比較指南
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Cefpodoxime proxetil for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包裝
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他說明
Sales restrictions may apply.
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Vasu Kumar Kakumanu et al.
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 128(3), 439-445 (2008-03-04)
Cefpodoxime proxetil (CP) is a prodrug with poor oral bioavailability because of its metabolism to Cefpodoxime acid (CA) in luminal contents and intestinal epithelial cells. In the present investigation, regional variability in different segments of the gastrointestinal tract vis-à-vis solubility
Naoto Fukutsu et al.
Chemical & pharmaceutical bulletin, 54(10), 1469-1472 (2006-10-04)
Cross-contamination is a critical issue for pharmaceutical manufacturing, especially for beta-lactam antibiotics. Thus, an analytical method for the simultaneous determination of beta-lactam antibiotics cefmetazole (CMZ) and cefpodoxime proxetil (CPDXPR) contaminants in non-beta-lactam pharmaceuticals was developed using high-performance liquid chromatography-tandem mass
Amrita Bajaj et al.
Drug development and industrial pharmacy, 39(5), 635-645 (2012-05-09)
Lipid based drug delivery systems have gained prominence in last decade for drugs with dissolution rate limited oral bioavailability. To improve the solubility, permeability and oral bioavailability of cefpodoxime proxetil, β-lactam antibiotic. It is BCS Class IV drug having solubility
Md Salim Shakur et al.
Indian pediatrics, 44(11), 838-841 (2007-12-07)
In order to evaluate clinical and bacteriological efficacy of Cefpodoxime Proxetil (CP) in typhoid fever in comparison to cefixime (CF), we assessed 140 children with suspected typhoid fever. Fulfilling inclusion criteria finally 40 culture confirmed typhoid fever were allocated in
Hakki Yilmaz et al.
Current drug safety, 8(2), 145-147 (2013-07-13)
We report a case of acute interstitial nephritis (AIN) and immune hemolytic anemia (IHA) associated with cefpodoxime therapy. A patient with a recent history of cefpodoxime proxetil treatment presented with elevated serum creatinine, oliguria, nausea, vomiting, and dyspnea. Evidence of
Active Filters
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務
